IMMUNOLOGICAL CLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIAS
Abstract
Background. ALL is a malignant blood disease and lymphoblasts have origin in B or T lymphatic cell line. In 1997 established new World Health Organisation classification (WHO classification) of malignant haematological diseases realizes the importance of cellular immunological markers (immunophenotype) and chromosomal abnormalities (cytogenetics). Based on both findings we may distribute the patients in low, intermediate and high risk groups and the outcome of such distribution is risk adopted ALL treatment strategy. On Clinical department of haematology (CDH) we have decided to overview immunophenotype characteristics of all ALL patients during the January 1, 1995–December 31, 2001 period.
Methods and results. During the January 1, 1995–December 31, 2001 period on CDH we have treated 44 patients: 22 males and 22 females. With flow cytometer Coulter Epics XL MCS we have performed first primary antibody panel for acute leukemias antigens (CD2, CD7, CD10, CD19, CD34, cCD3, cCD13, cCD22, MPO, TdT), followed by secondary panel. The later have included antigen CD20, CD23, membrane and/or cytoplasmatic immunoglobulins or their light chains monoclonal antibodies for B-ALL and antigen CD3, CD4, CD5 and CD8 monoclonal antibodies for T-ALL subsets. Besides immunophenotyping we have evaluated all ALL patients also morphologically according to FAB classification (French-AmericanBritish classification), which is an old classification based solely on morphology.
32/44 (73%) patients have had immunophenotypic B-ALL, and 12/44 (27%) T-ALL. Subgroups distribution of B-ALL immunophenotype were: pro-B 4/44 (9%), »common«-B 18/44 (41%), pre-B 5/44 (11.5%) and mature B 5744 (11.5%) and for T-ALL immunophenotype were: pro-T 2/44 (4.5%), pre-T 5/44 (11.5%), cortical-T 4/44 (9%) and mature-T 1/44 (2%). Our results are quite comparable with the available data from the literature, despite the fact that newest immunological markers such as CD1a, CD79a and CD22 were not available until last year.
ALL morphology does not determine ALL immunophenotype, with the exception of L3 subtype, which usually coincidences with mature B immunophenotype. The commonest morphological variant is L2 subtype, which we have seen in 35/44 (80%) patients and was equally distributed among B and T immunophenotypic subgroups.
Conclusions. Determination of ALL immunophenotype is one of the cruical tests for the evaluation of long-term ALL prognosis. Because of the later, every newly diagnosed ALL must be immunophenotyped. Immunophenotype is not the only ALL prognostic factor, but in combination with the others such as cytogenetics, patients age, leukocyte count at diagnosis, we can put together »ALL prognostic mosaic«, followed by an optimal ALL treatment strategy.
Downloads
References
Hernandez JA, Land KJ, McKenna RW. Leukemias, myeloma, and other lymphoreticular neoplasms. Cancer 1995; 75: 381–93.
Harris NL, Laffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J. Lymphoma classification – from controversy to consensus: the REAL and WHO classification of lymphoid neoplasms. Annals of Oncol 2000; 11: Suppl: 3–10.
Bennett JM, Catovsky D, Daniel MT et al. Proposals for the classification of the acute leukaemias. Br J Haematol 1976; 33: 451–8.
Matutes E, Morilla R, Catovsky D. Immunophenotyping. In: Lewis SM, Bain BJ, Bates I eds. Dacie and Lewis practical haematology. 9th ed. London: Churchill-Livingstone, 2001: 297–314.
Ludwig WD, Raghavacher A, Thiel E. Immunophenotypic classification of acute lymphoblastic leukemia. Baillieres Clin Haematol 1994; 7: 235–45.
Bene MC, Castoldi G, Knapp W et al. Proposals for the immunological classification of acute leukemias. Leukemia 1995; 9: 1783–6.
Ching-Hon P. Acute lymphoblastic leukemia. In: Beutler E, Coller BS, Lichtman MA, Kipps TJ, Seligsohn U eds. Williams hematology. 6th ed. New York: McGraw Hill, 2001: 1141–61.
Larson RA, Dodge RK, Bloomfield CD, Schiffer CA. Treatment of biologicaly determined subsets of acute lymphoblastic leukemia in adults: Cancer and leukemia group B-studies. In: Buchner T, Hiddeman W, Wormann B, Ritter J, Schellong G eds. Acute leukemias VI: Prognostic factors and treatment strategies. Berlin: Springer-Verlag, 1997: 677–89.
Thomas X, Danaila C, Le QH et al. Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period. Leukemia 2001; 15: 1811–22.
Boucheix C, David B, Sebban C et al. Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters and outcome: An analysis of a prospective trial, including 562 tested patients (LALA87). Blood 1994; 84: 1603–11.
Czuczman MS, Dodge RK, Carleton C et al. Value of immunophenotype in intensively treated adult acute lymphoblastic leukemia: Cancer and leukemia group B study 8364. Blood 1999; 93: 3931–9.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
